| Literature DB >> 35198583 |
Io Antonopoulou1, Eleftheria Sapountzaki1, Ulrika Rova1, Paul Christakopoulos1.
Abstract
Plant biomass is a magnificent renewable resource for phytochemicals that carry bioactive properties. Ferulic acid (FA) is a hydroxycinnamic acid that is found widespread in plant cell walls, mainly esterified to polysaccharides. It is well known of its strong antioxidant activity, together with numerous properties, such as antimicrobial, anti-inflammatory and neuroprotective effects. This review article provides insights into the potential for valorization of FA as a potent antiviral agent. Its pharmacokinetic properties (absorption, metabolism, distribution and excretion) and the proposed mechanisms that are purported to provide antiviral activity are presented. Novel strategies on extraction and derivatization routes, for enhancing even further the antiviral activity of FA and potentially favor its metabolism, distribution and residence time in the human body, are discussed. These routes may lead to novel high-added value biorefinery pathways to utilize plant biomass toward the production of nutraceuticals as functional foods with attractive bioactive properties, such as enhancing immunity toward viral infections.Entities:
Keywords: antiviral activity; enzymatic derivatization; extraction; ferulic acid; immunity; metabolism; nutraceuticals; plant biomass
Year: 2022 PMID: 35198583 PMCID: PMC8860162 DOI: 10.3389/fnut.2021.777576
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
Figure 1(A) Hydroxycinnamic acids; FA, ferulic acid; SA, sinapic acid; CA, caffeic acid; pCA, p-Coumaric acid. (B) Example of feruloylated glucuronoarabinoxylan, where FA is esterified to the O-5 hydroxyl group of a-L-arabinofuranose. Cross-linkage between hemicellulose chains is an example of a 5,5′ FA dehydrodimer. FA linkage with lignin is also demonstrated.
Examples of reported methods on the pretreatment of plant biomass and further purification of FA.
|
|
|
|
|
|
|---|---|---|---|---|
| Wheat bran | Defatted with hexane, alkaline hydrolysis, acidification to pH 2, extraction with ethyl ester (three times) | Counter-current chromatography followed by pH-zone-refining counter-current chromatography | 98–99% purity | ( |
| Brewer's spent grain | Dilute sulfuric acid hydrolysis followed by alkaline hydrolysis | Ethanol extraction | 46.17 mg/100 g BSG | ( |
| Sugar cane bagasse | Alkaline hydrolysis | Adsorption by powdered activated charcoal and further treatment by anion macroporous resin exchange chromatography | FA could be totally washed out by 0.2 mol/L NaOH, high purity obtained | ( |
|
| Microwave-assisted ethanol extraction | High-speed counter-current chromatography | >98% purity | ( |
| Wheat bran | Enzymatic hydrolysis | Nanofiltration membranes (MWCO between 600 and 800 g mol−1) | 85% retention for FA | ( |
| Destarched wheat bran | Alkaline hydrolysis | Adsorption on Amberlite XAD4 resin | 49.9 mg FA/g resin, 99.5% recovery using methanol as eluent | ( |
| Wheat bran | Ultrasound-assisted ethanol extraction | Adsorption on magnetic nanoparticles | 77.9–97.5% recovery | ( |
| Corn fiber | Alkaline hydrolysis | Ultrafiltration membrane (Nadir UP 150) | 98.0% rejection of arabinoxylans | ( |
| Corn bran | Alkaline hydrolysis | Adsorption on mesoporous carbon | Much higher adsorption capacity for FA than those of activated charcoal, other activated carbon materials, and macroporous resins | ( |
| Sugar beet pulp, maize bran, wheat bran, rice bran | Enzymatic hydrolysis | Adsorption on Amberlite XAD-4 resin | 1.9/5.5 mg FA/g | ( |
| Brewer's spent grain | Alkaline hydrolysis | Adsorption by synthetic resin (Lewatit VPOC1064 MD PH®) | Partial purification | ( |
| Wheat bran | Enzymatic hydrolysis | Demineralization by homopolar electrodialysis, adsorption on weak anion-exchange resin (Amberlyst A21- Dow) | 52% of FA was released by enzymatic hydrolysis, of which 83% was crystallized with purity 90–95% | ( |
| Flax shives, wheat bran and corn | Alkaline hydrolysis, pressurized | Ultrafiltration and ethanol solubilization/centrifugation cycles (2 times) | 56% efficiency, clean TLC and FTIR (FA) | ( |
| Corn bran | Alkaline hydrolysis | Ultrafiltration (5,000 Da MWCO), nanofiltration | 91.8% recovery, 8.47 g FA crystals/kg corn bran with 84.45% purity | ( |
| Grass | Dilute sulfuric acid followed by alkaline hydrolysis | Ethanol extraction | 30.9 g FA/100 g grass | ( |
| Adsorption with activated charcoal or polyvinylpolypyrrolidone (PVPP) | 3.3 g FA/100 g grass | |||
| 0.5 g FA/100 g grass | ||||
| Sugar beet pulp | Twin-screw extraction and enzymatic hydrolysis | Microfiltration (3 μm), adsorption on activated charcoal | 50% purity (FA), 6 cycles to achieve 97% efficiency | ( |
| Wheat bran | Enzymatic hydrolysis | Adsorption on weak anionic resin | 15 g/L, 67% recovery | ( |
Figure 2Absorption, metabolism and excretion of FA in human body. The route of FA is described with orange arrows, while the metabolic modifications are shown in blue.
Antiviral effect of plant extracts containing FA.
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
| Aqueous extraction of leaves, filtration and spray drying | FA, caffeic acid, rosmarinic acid | HSV-1 | Complete viral inhibition after 6 h at maximum tolerable concentration of the extract | Maximum tolerable concentration: 0.25% | ( | ||
| – | FA, isoferulic acid (pure compounds) | RSV | 42.8% lower MIP-2 levels compared to the control at 500 μM FA | Cells >95% viable when treated with 500 μM compound | ( | ||
| Successive hot water extraction of whole plant, filtration, concentration in vacuo and lyophilization | Baicalein, baicalin, luteolin, aucubin, caffeic acid, chlorogenic acid, FA, | HSV-2 | EC50 = 843 μg/ml | CC50 = 1,809 μg/ml | ( | ||
| - | FA (pure compound) | ADV-8 | EC50 = 52.5 μg/ml | CC50 = 92.6 μg/ml | |||
| ADV-11 | EC50 = 23.3. μg/ml | ||||||
| Successive methanol extraction of the plant latex, filtration and evaporation, followed by silica gel chromatography eluting with hexane and after through hexane–ethyl acetate, drying under reduced pressure | Caffeic acid, 3,4-dihydrobenzoic acid, | HSV-1 | 100% blocked replication of the virus and virucidal activity when incubated with the extract for 1 h with 78 μg/ml extract | No cytotoxic effect at tested concentrations | ( | ||
| ECV-11 | |||||||
| ADV | |||||||
|
| Cold-pressing of leaves, filtration and freeze drying | 7.59% w/w FA, 0.33% w/w, quercetin, 0.16% w/w kaempferol | EV71 | IC50 = 35.88 μg/ml (plaque reduction assay on RD cells) | No cytotoxicity at a range of 1–500 μg/ml | ( | |
| IC50 = 40.82 μg/ml (cell-based FRET assay) | |||||||
| CVA16 | IC50 = 42.91 μg/ml (plaque reduction assay on RD cells) | ||||||
| IC50 = 47.87 μg/ml (cell-based FRET assay) | |||||||
|
| Extraction of dried leaves with methanol or water, centrifugation and evaporation–redissolution with distilled water | 4-hydroxybenzoic acid, caffeic acid, rutin, FA, coumaric acid epigallocatechin gallate, quercetin, myricetin, kaempferol | PRRSV | Inhibition observed with 25 μg of methanol extract or 75–100 μg of water extract | – | ( | |
| Propolis | Propolis Extract ACF® (specific purified ethanol extract) | Aromatic acids incl., E- | HSV-1 | Inhibition of adsorption in cells at 0.1 mg/ml when incubation was ≥ 60 min | CC50 = 0.13 mg/ml | ( | |
| HSV-1/HSV-2 | Virucidal effect for extract concentration ≥ 10 mg/ml and incubation for at least 15 min | ||||||
| Ethanol extract, chloroform soluble fraction | Kaempferol, galangin, quercetin, fisetin, chrysin, luteolin, acacetin, caffeic acid, FA, | HRV-4 | IC50 = 5.0 μg/ml (SRB method) | CC50 = 82.3 μg/ml | ( | ||
| - | FA (pure compound) | HRV-2 | IC50 = 175.1 μM | CC50 > 5,000 μM | |||
| HRV-3 | IC50 = 248.7 μM | ||||||
| HRV-4 | IC50 = 232.3 μM | ||||||
|
| Successive extraction of dried plant with methanol, sonication, vacuum evaporation | Leaves | Gallic acid, FA, o-coumaric acid, quercetin | H1N1 | IC50 = 46.69 μg/ml (SRB method) | CC50 = 1,026 μg/ml | ( |
| Stem | H1N1 | IC50 = 22.43 μg/ml | CC50 = 100 μg/ml | ||||
|
| Leaves | H1N1 | IC50 = 60.09 μg/ml | CC50 = 100 μg/ml | |||
| Stem | H1N1 | IC50 = 33.98 μg/ml | CC50 = 50 μg/ml | ||||
|
| Leaves | H1N1 | IC50 = 33.36 μg/ml | CC50 = 20 μg/ml | |||
| Stem | H1N1 | IC50 = 23.60 μg/ml | CC50 = 40 μg/ml | ||||
|
| Leaves | H1N1 | IC50 = 65.99 μg/ml | CC50 = 100 μg/ml | |||
| Stem | H1N1 | IC50 = 20.50 μg/ml | CC50 = 18.30 μg/ml | ||||
| Calyses extracted in deionized distilled boiling water and filtered | Anthocyanins, phenolic acids, organic acids, saponins, and alkaloids, including malic acid, protocatechuic acid and FA (based on literature) | FCV-F9 | Viral titer undetectable after 15 min with 40 or 100 mg/ml | Cytotoxicity observed at > 40 mg/ml | ( | ||
| MNV-1 | Viral titer undetectable after 24 h with 40 mg/ml | ||||||
| HAV | Viral titer undetectable after 24 h with 40 mg/ml | ||||||
| – | FA (pure compound) | FCV-F9 | Viral titer undetectable after 15 min after 3 h with 0.5 or 1 mg/ml | – | |||
| MNV-1 | 0.94 logPFU/ml reduction after 24 h at 1 mg/ml | ||||||
| HAV | No significant reduction in viral titers after 24 h | ||||||
| Extraction of dried stem bark with acetone, filtration and drying by evaporation | Benzoic acid, quinol, myricetin, salicylic acid, rutin, ellagic acid, vanillic acid, | TMV | 72.22% inhibition (protective effect) 50.43% inhibition (curative effect) 33.33% inhibition (inactivating effect) at 100 μg/ml | – | ( | ||
| Hydroalcoholic extract of female inflorescences | Chlorogenic acid, t-FA (0.078 μg/mg), gallic acid, | Influenza (PR8, pH1N1, NWS, ULSTER) | IC50 = 99 μg/ml for the PR8 strain | Cell viability > 90% for 20–140 μg/ml | ( | ||
| Extraction of leaves with 70% methanol, filtration and drying by vacuum evaporation | Quercetin, myricetin, gallic acid, caffeic acid, FA (0.37 mg/g DE) | HCV | IC50 = 11.44 μg/ml | CC50 > 200 μg/ml | ( | ||
| Leaf extraction in 95% ethanol: 5% acetic acid, filtration and evaporation | Chlorogenic acid, caffeic acid, FA (0.0195 mg/100 g DW), gallic acid, rutin, quercetin | MS2 | 3.47 logPFU/ml (reduction of viral titer) | – | ( | ||
| Av-05 | 5.78 logPFU/ml | ||||||
| Mixing of dried peels with 95% ethanol: 5% acetic acid, filtration, sonication of the residue with ethanol, filtration of the sonicated residue, mixing of the two supernatants and concentration | Gallic acid, chlorogenic acid, caffeic acid, FA (3.29 mg/100 g DW), rutin, quercetin | MS2 | 3.9 logPFU/ml (reduction of viral titer) | – | ( | ||
| Av-05 | 2.8 logPFU/ml | ||||||
|
| Extraction of the whole plant with ethanol (soaking method), filtration and evaporation | Gallic acid, FA (26.86 mg/kg), catechin, quinol, syringic acid, caffeic acid, vanillic acid, ellagic acid, cinnamic acid, | TMV | 65.38% inhibition (protective effect); 95.73% inhibition (inactivating effect) | – | ( | |
| – | FA isolated from the extract | H1N1 | IC50 = 140 μg/ml | CC50 = 702 μM | ( | ||
| Rice bran | – | Isolated cycloartenol ferulate | HIV-1 | IC50 = 2.2 μg/ml (reverse transcriptase inhibition assay) | – | ( | |
| Isolated 24-methylenecycloartanol ferulate | |||||||
| 94% inhibition (4 mg/ml) | |||||||
| – | HIV-1 | IC50 = 1.9 μg/ml | |||||
| 89% inhibition (4 mg/ml) | |||||||
| Soaking of dried plant roots with dichloromethane | α-Amyrin, tetradecanal, palmitic acid, octadecanal, γ-sitosterol, β-amyrin, 28-hydroxyoctacosyl ferulate | HSV-1 | 93% inhibition (protective effect at 100 μg/ml) | CC50 >200 μg/ml | ( | ||
| – | 28-hydroxyoctacosyl ferulate isolated from extract | HSV-1 | EC50 = 21.6 μg/ml | CC50 >200 μg/ml | |||
| HSV-2 | EC50 = 86.5 μg/ml | ||||||
| Extraction of dried fruits with 80% ethanol, concentration and elution with 40% ethanol through column chromatography | Procyanidin B2, unspecified ferulic acid derivatives, two ferulic acid | IFV | IC50 = 22 μg/ml (viral inhibition plaque assay) | CC50 = 160 μg/ml | ( | ||
Conditions or fractions that offer highest antiviral effect in the respective study; HSV, herpes simplex virus; RSV, respiratory syncytial virus; ADV, adenovirus; ECV, echovirus; EV, enterovirus; CV, coxsackievirus; PPRSV, porcine reproductive and respiratory syndrome virus; HRV, human rhinovirus; H1N1, influenza A virus subtype; FCV, feline calicivirus; MNV, murine noronivirus; HAV, hepatitis A virus; TMV, tobacco mosaic virus; HCV, hepatitis C virus; MS2, Av-05, bacteriophage; HIV, human immunodeficiency virus; IFV, influenza virus; EC.
Antiviral effect of FA derivatives.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| |||||
| FA polymers |
| HIV-1 | IC50 = 1.0 μg/ml | >30 kDa | ( |
| Example: diferulate, triferulate | |||||
| FA amide of 3-aminomethyl glaucine |
| HRV-14 | IC50 = 12.00 μM | - | ( |
| FA amides |
| TMV | 40.7% protective effect | R1: n-Pr; | ( |
| Hydrogenated FA amides |
| TMV | 27.3% protective effect | R1: Me | ( |
|
| TMV | 15.2% protective effect | R1: | ( | |
| α,β-unsaturated amide derivatives of FA with an α-aminophosphonate moiety |
| TMV | EC50 = 180.37 μg/ml (protective effect) | R1: 4-Cl | ( |
| EC50 = 285.42 μg/ml (curative effect) | R2: 4-CF3-Ph | ||||
| CMV | EC50 = 216.30 μg/ml (protective effect) | ||||
| EC50 = 284.67 μg/ml (curative effect) | |||||
| Trans-FA derivatives containing acylhydrazone moiety |
| TMV | 18.8% curative effect | R1: PhCH2 | ( |
| 23.0% protective effect | R2: 2-Th | ||||
| 94.2% inactivating effect | |||||
| EC50 = 36.59 μg/ml | |||||
| FA sulfonamides |
| TMV | 39.8% curative effect | R1: -C2H5 | ( |
| 59.7% protective effect | R2: 4-NO2-Ph | ||||
| EC50 = 84.80 μg/ml | |||||
| Myricetin derivatives with an FA amide scaffold |
| TMV | 55.5% curative effect | R: 4-Br, | ( |
| FA 3-amino derivatives/esters |
| H1N1 | IC50 =90.0 μg/ml | R1: CH2(CH3) | ( |
| R2: CH(CH3)2 | |||||
| R3: NO2 | |||||
| FA derivatives with a quinazoline moiety |
| TMV | 60.8% curative effect | R1: 2-OCH3-Ph | ( |
| 78.2% protective effect | R2: 4-oxoquinazolin-3(4H)-yl-methyl | ||||
| 90.8% inactivating effect | |||||
| CMV | 58.1% curative effect | R1: 2-OCH3-4-allyl-Ph | |||
| 69.8% protective effect | |||||
| R2:4-oxoquinazolin-3(4H)-yl-methyl | |||||
| 78.2% inactivating effect | |||||
| Trans-FA esters with a chalcone group |
| TMV | 63.9% curative effect | R: Me | ( |
| 64.6% protective effect | Ar: 2-F-Ph | ||||
| 92.3% inactivating effect | |||||
| EC50 = 214.20 μg/ml | |||||
| FA derivatives containing dithioacetal moiety |
| TMV | 62.7% curative effect | R1: 3-OCH3-4-OCOCH3 | ( |
| 52.3% protective effect | |||||
| 73.8% inactivating effect | R2: 2-OCH3 | ||||
| EC50=73.7 μg/ml | R3: -(CH2)2OH | ||||
|
| TMV | 62.5% curative effect | R1: 3-OCH3-4-OCOCH3 | ||
| 61.8% protective effect | R2: H | ||||
| R3: -(CH2)2OH | |||||
| 83.5% inactivating effect | |||||
| EC50= 50.7 μg/ml | |||||
|
| TMV | 48.% curative effect | R1: H | ||
| 48.% protective effect | R2:H | ||||
| 53.% inactivating effect | |||||
| EC50=355.6 μg/ml | |||||
|
| |||||
| FA rutinoside |
| FCV | 40% increase of cell viability | – | ( |
| FA β-sitosterol ester |
| SARS-CoV-2 | Binding energy = −7.8 kcal/mol (molecular docking simulation with SARS-CoV-2 3CLpro) | – | ( |
| ( | |||||
HIV, human immunodeficiency virus; HRV, human rhinovirus; TMV, tobacco mosaic virus; CMV, cucumber mosaic virus; H1N1, influenza A virus subtype; FCV, feline calicivirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus; EC.
Figure 3A route for FA valorization toward developing antiviral agents.